Barclays maintains Legend Biotech at Overweight, lowers price target to $61 from $68

Barclays kept Legend Biotech's rating at Overweight but reduced its price target to $61 from $68. The new target suggests a 198.9% upside from the Nov 10 close of $20.41, according to the bank.

Original reporting
Published Nov 11, 2026, 3:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 3:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Barclays maintains Legend Biotech at Overweight, lowers price target to $61 from $68 — source image
Decision brief

The 30-second read

Med
01

Why it matters

The downgrade may trigger short-term selling pressure, but the Overweight stance leaves room for upside if new data emerges.

02

Market read

Analyst target cut on a microcap biotech can cause immediate price movement, offering a short-term trading signal.

03

What to watch

Potential pipeline milestones not reflected in the downgrade.

Relevance 6/10Novelty 6/10Timing: today

Background

Barclays maintains an Overweight rating but reduces its price target, a typical analyst action that can move small-cap stocks.

Market effects

May affect sentiment toward other biotech microcaps.

Limited to US biotech sector.

Low

Counterpoint

The target cut could be overdone if upcoming trial data exceeds expectations.

Key entities

  • Barclays

    Equity research firm issuing the rating and target change.

  • Legend Biotech

    US-listed biotech firm (ticker LGND).

Related articles

$LEGNMedAI 8/10

Legend Biotech (LEGN) Q3 2026 Earnings Call Transcript

Legend Biotech (LEGN) reported Q3 2026 earnings, with CARVYKTI net trade sales up 36% YoY to $710M. Growth driven by U.S. and international adoption. The company presented long-term data supporting CARVYKTI's use in earlier multiple myeloma lines and received FDA clearance for LB2501. Legend Biotech aims for profitability in 2026 and has $853M in cash reserves.

$LEGNMedAI 8/10

Legend Biotech Corp (LEGN) Q3 2026 Earnings Call Highlights: CARVYKTI Sales Jump 36%

Legend Biotech (LEGN) reported a 36% increase in CARVYKTI sales for Q3 2026, but U.S. sales were flat. Management noted slower-than-expected U.S. growth and launch delays in ex-U.S. markets. R&D expenses declined 16% year-over-year, but future spending may increase. CARVYKTI's U.S. sales mix shifted toward earlier lines, and the company expects double-digit growth in 2027. LB2501 dose level 3 showed lower efficacy than dose level 2, and there were no updates on LB2505.

$LEGNMed

What Legend Biotech (LEGN) Said on Its Q3 Earnings Call

Legend Biotech (LEGN) reported a 32% year-over-year revenue increase, with adjusted net income of $55.6M. CEO Ingrid Zhang expects CARVYKTI to generate over $5B in peak sales. The company improved gross margins and reduced R&D expenses. Legend also received FDA clearance for a clinical study of LB2501 and shared positive interim data. The company remains debt-free with $853M in cash equivalents.

$LEGNHigh

Why is Legend Biotech stock sliding today?

Legend Biotech (LEGN) stock fell 13.2% pre-market after reporting a Q3 2026 GAAP loss of $0.13 per share, missing estimates. Revenue of $359.5M beat expectations, but license revenue declined. The company announced a new CEO and FDA clearance for LB2501, but these were overshadowed by the earnings miss and broader market declines.

$LEGNMed

Legend Biotech shares fall 2% despite revenue beat

Legend Biotech (LEGN) reported Q3 2026 revenue of $359.5M, beating estimates. Shares fell 2.18% despite results. Collaboration revenue rose to $353.2M, driven by CARVYKTI sales. Net income was $51.7M, reversing a prior-year loss. R&D and admin expenses declined. FDA cleared IND for LB2501. Cash reserves were $853M.